Causes and management of chronic hepatitis C in treatment experienced patients

被引：0
作者：
Beltsis, A. [1 ]
Ilias, A. [1 ]
机构：
[1] G Papanikolaou Hosp, Dept Gastroenterol, Thessaloniki, Greece
来源：
ANNALS OF GASTROENTEROLOGY | 2009年 / 22卷 / 04期
关键词：
Hepatitis C Virus; Pegylated(PEG)-interferon + ribavirin treatment; Consensus Interferon; Difficult-to-treat; Re-lapsers; Non-Responders;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Chronic Hepatitis C is a major public health issue, affecting >2% of the worlds population. Combination treatment with pegylated interferon alfa and ribavirin is successful in achieving long-term viral suppression in about 50% of patients. The ever-growing population of relapsers and non-responders to PEG-IFN + ribavirin poses a difficult clinical problem. We investigate the causes of treatment failure, whether virus-related (HCV genotype, quasispecies diversity and viral load) or host-related (age, sex, race, fibrosis/cirrhosis, obesity and insulin resistance) and review the results of recently published trials on the treatment of relapsers and non-responders to PEG-IFN + ribavirin, focusing on the prognostic value of week 12 HCV-RNA measurements.
引用
收藏
页码：248 / 254
页数：7
相关论文
共 56 条
  • [1] Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial
    Alric, L
    Duffaut, M
    Selves, J
    Sandre, K
    Mularczyck, M
    Izopet, J
    Desmorat, H
    Bureau, C
    Chaouche, N
    Dalbergue, B
    Vinel, JP
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (02) : 272 - 278
  • [2] Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5
    Antaki, N.
    Hermes, A.
    Hadad, M.
    Ftayeh, M.
    Antaki, F.
    Abdo, N.
    Kebbewar, K.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 (05) : 383 - 386
  • [3] Retreating Chronic Hepatitis C with Daily Interferon Alfacon-1/Ribavirin After Nonresponse to Pegylated Interferon/Ribavirin: DIRECT Results
    Bacon, Bruce R.
    Shiffman, Mitchell L.
    Mendes, Flavia
    Ghalib, Reem
    Hassanein, Tarek
    Morelli, Giuseppe
    Joshi, Shobha
    Rothstein, Kenneth
    Kwo, Paul
    Gitlin, Norman
    [J]. HEPATOLOGY, 2009, 49 (06) : 1838 - 1846
  • [4] Bakr I, 2006, GUT, V55, P1183, DOI [10.1136/gut.2006.078147, 10.1136/gut.2005.078147]
  • [5] Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy
    Benhamou, Y
    Di Martino, V
    Bochet, M
    Colombet, G
    Thibault, V
    Liou, A
    Katlama, C
    Poynard, T
    [J]. HEPATOLOGY, 2001, 34 (02) : 283 - 287
  • [6] The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon
    Blatt, LM
    Davis, JM
    Klein, SB
    Taylor, MW
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (07) : 489 - 499
  • [7] Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-α therapy
    Böcher, WO
    Schuchmann, M
    Link, R
    Hillenbrand, H
    Rahman, F
    Sprinzl, M
    Mudter, J
    Löhr, HF
    Galle, PR
    [J]. LIVER INTERNATIONAL, 2006, 26 (03) : 319 - 325
  • [8] Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon
    Boulestin, A
    Kamar, N
    Sandres-Sauné, K
    Legrand-Abravanel, F
    Alric, L
    Vinel, JP
    Rostaing, L
    Izopet, J
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (03) : 365 - 371
  • [9] Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
    Carlsson, T
    Reichard, O
    Norkrans, G
    Bläckberg, J
    Sangfelt, P
    Wallmark, E
    Weiland, O
    [J]. JOURNAL OF VIRAL HEPATITIS, 2005, 12 (05) : 473 - 480
  • [10] Centers for Disease Control and Prevention (US). Division of Viral Hepatitis, US DIS BURD DAT 1980
123456